Ann: US patent allowed for CHM 0201 (CORE-NK) technology, page-12

Thanks, Dalts. It really surprises me that the pipeline of assets and the timeline for development of such impressive assets has clearly been flying under the radar!

Friday's ann highlights how, from this one simple CORE-NK technology, CHM has designed and is developing a number of synergistic plattorms. If if weren't for the fact that biotech is time consuming, you could almost get away with saying that CHM is going to be banging out assets one after the other.... well, its not far from it when they are already initiate Phase 1b trials before Phase 1a trials conclude and have more than one combo trial happening at the same time. The depth of the experts behind CHM too is highly significant. I'm starting to get the impression that maybe monetisation of any number of platforms is not all that far off (esp at the rate that things are progressing).

The Smallhats article that pinch2020 kindly shared, captures the significance of Friday's ann beautifully: